Eileen McDermott

Publish Date
Organizations Tell USPTO Proposed 2025 Fees ‘Misuse’ Office’s Fee Setting Authority
IPWatchdog
Biden’s shortsighted patent attacks threaten American innovation

The Biden administration is quietly advancing a proposal that could devastate America’s high-tech economy. The White House says the plan is about...

The Hill
C4IP Comments RE: Setting and Adjusting Patent Fees During Fiscal Year 2025 (PTO-P-2022-0033)
Public Comments
C4IP Comments RE: Setting and Adjusting Patent Fees During Fiscal Year 2025 (PTO-P-2022-0033)
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
PharmaVoice
Former USPTO Officials Urge Vidal to Immediately Withdraw NPRM on Terminal Disclaimers
IPWatchdog
Ex-USPTO Directors Want Vidal To Withdraw Disclaimer Plans
Law360
Quintet of Ex-Patent Office Officials Slam Proposed Rulemaking
Bloomberg Law
Fact Check: Price Controls Would Not Make Diabetes Treatments More Accessible

Bringing a new therapeutic to market is a challenging and costly endeavor. Strong intellectual property protections, which enable manufacturers to recoup their...

C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents
IPWatchdog
Group chaired by former USPTO directors questions office’s AI guidance over ‘human contribution’
Inside AI Policy
Letters
C4IP Letter to Senate Judiciary Committee on 5/21 Hearing on Drug Prices

Dear Chairman Durbin and Ranking Member Graham: On behalf of the Council for Innovation Promotion (C4IP), we write in advance of your...

News:

News:

Organizations Tell USPTO Proposed 2025 Fees ‘Misuse’ Office’s Fee Setting Authority,

06/05/2024

Op-Eds:

Op-Eds:

Biden’s shortsighted patent attacks threaten American innovation,

06/04/2024

C4IP:

C4IP:

C4IP Comments RE: Setting and Adjusting Patent Fees During Fiscal Year 2025 (PTO-P-2022-0033),

06/03/2024

Resources:

Resources:

C4IP Comments RE: Setting and Adjusting Patent Fees During Fiscal Year 2025 (PTO-P-2022-0033),

06/03/2024

News:

News:

As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’,

05/30/2024

News:

News:

Former USPTO Officials Urge Vidal to Immediately Withdraw NPRM on Terminal Disclaimers,

05/29/2024

News:

News:

Ex-USPTO Directors Want Vidal To Withdraw Disclaimer Plans,

05/28/2024

News:

News:

Quintet of Ex-Patent Office Officials Slam Proposed Rulemaking,

05/28/2024

Blog:

Blog, Fact Checks:

Fact Check: Price Controls Would Not Make Diabetes Treatments More Accessible,

05/24/2024

News:

News:

C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents,

05/23/2024

News:

News:

Group chaired by former USPTO directors questions office’s AI guidance over ‘human contribution’,

05/21/2024

Resources:

Resources:

C4IP Letter to Senate Judiciary Committee on 5/21 Hearing on Drug Prices,

05/20/2024

Scroll to Top